Published in Oncology on January 01, 2001
Gemcitabine with or without continuous infusion 5-FU in advanced pancreatic cancer: a randomised phase II trial of the Italian oncology group for clinical research (GOIRC). Br J Cancer (2005) 1.18
Comparison of the efficacy and the toxicity between gemcitabine with capecitabine (GC) and gemcitabine with erlotinib (GE) in unresectable pancreatic cancer. J Cancer Res Clin Oncol (2012) 0.82
Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet (2001) 5.75
Randomized clinical trial on the effect of coffee on postoperative ileus following elective colectomy. Br J Surg (2012) 4.01
Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma. Br J Surg (2004) 3.90
Fewer adhesions induced by laparoscopic surgery? Surg Endosc (2004) 3.11
Influence of resection margins on survival for patients with pancreatic cancer treated by adjuvant chemoradiation and/or chemotherapy in the ESPAC-1 randomized controlled trial. Ann Surg (2001) 2.94
IL-17 stimulates intraperitoneal neutrophil infiltration through the release of GRO alpha chemokine from mesothelial cells. J Immunol (2000) 2.93
The role of DNA mismatch repair in platinum drug resistance. Cancer Res (1996) 2.88
Desmoplastic reaction in pancreatic cancer: role of pancreatic stellate cells. Pancreas (2004) 2.85
Acute necrotizing pancreatitis: treatment strategy according to the status of infection. Ann Surg (2000) 2.73
The bmi-1 oncoprotein is differentially expressed in non-small cell lung cancer and correlates with INK4A-ARF locus expression. Br J Cancer (2001) 2.67
Cloning of a gene highly overexpressed in cancer coding for a novel KH-domain containing protein. Oncogene (1997) 2.58
Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. J Clin Invest (1992) 2.54
Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry (1999) 2.50
The role of DNA mismatch repair in drug resistance. Clin Cancer Res (1998) 2.49
Pancreatic fistula after pancreatic head resection. Br J Surg (2000) 2.44
Use of accurate diagnostic criteria may increase incidence of stercoral perforation of the colon. Dis Colon Rectum (2000) 2.41
Role of octreotide in the prevention of postoperative complications following pancreatic resection. Am J Surg (1992) 2.38
Incisional hernia rate 3 years after midline laparotomy. Br J Surg (2013) 2.37
Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling. Gut (2008) 2.36
Randomized controlled multicentre study of the prevention of complications by octreotide in patients undergoing surgery for chronic pancreatitis. Br J Surg (1995) 2.36
Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40. J Clin Pathol (2006) 2.33
Meta-analysis of randomised adjuvant therapy trials for pancreatic cancer. Br J Cancer (2005) 2.32
Chemotherapy vs supportive care in advanced non-small-cell lung cancer. Results of a meta-analysis of the literature. Chest (1994) 2.32
Mucin (MUC) gene expression in human pancreatic adenocarcinoma and chronic pancreatitis: a potential role of MUC4 as a tumor marker of diagnostic significance. Clin Cancer Res (2001) 2.24
The cell-surface heparan sulfate proteoglycan glypican-1 regulates growth factor action in pancreatic carcinoma cells and is overexpressed in human pancreatic cancer. J Clin Invest (1998) 2.22
Systematic review and meta-analysis of technique for closure of the pancreatic remnant after distal pancreatectomy. Br J Surg (2005) 2.18
Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res (1993) 2.15
Retroperitoneal endoscopic neurectomy for nerve entrapment after hernia repair. Br J Surg (1997) 2.12
Missed diaphragmatic injuries and their long-term sequelae. J Trauma (1998) 2.09
Characterisation of acute murine dextran sodium sulphate colitis: cytokine profile and dose dependency. Digestion (2000) 2.09
Overexpression of acidic and basic fibroblast growth factors in human pancreatic cancer correlates with advanced tumor stage. Cancer Res (1993) 2.08
The problem of the poor control arm in surgical randomized controlled trials. Br J Surg (2012) 2.08
Incidence, risk factors, and prevention of biliary tract injuries during laparoscopic cholecystectomy in Switzerland. World J Surg (2001) 2.07
Circulatory and respiratory complications of carbon dioxide insufflation. Dig Surg (2004) 2.06
Neuroimmune appendicitis. Lancet (1999) 2.05
Overexpression of HER2/neu oncogene in human pancreatic carcinoma. Hum Pathol (1993) 2.05
More is not always better: a case for low-dose leucovorin. J Clin Oncol (1993) 2.03
Management of acute pancreatitis: from surgery to interventional intensive care. Gut (2005) 2.02
[The diagnostic value of the amino acid absorption test in detection of a disorder of exocrine pancreatic function]. Z Gastroenterol (1992) 2.02
Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life. Eur J Cancer (1999) 1.99
Carcinoid of the ampulla of Vater. Clinical characteristics and morphologic features. Cancer (1994) 1.97
Cyclin D1 overexpression in bronchial epithelia of patients with lung cancer is associated with smoking and predicts survival. J Clin Oncol (2003) 1.94
Systematic review and meta-analysis of standard and extended lymphadenectomy in pancreaticoduodenectomy for pancreatic cancer. Br J Surg (2007) 1.92
Late mortality in patients with severe acute pancreatitis. Br J Surg (2001) 1.92
High coincidence of Mirizzi syndrome and gallbladder carcinoma. Surgery (1997) 1.89
Effect of preoperative biliary drainage on surgical outcome after pancreatoduodenectomy. Am J Surg (2001) 1.87
Robot-assisted abdominal surgery. Br J Surg (2004) 1.85
VEGF expression by mesenchymal stem cells contributes to angiogenesis in pancreatic carcinoma. Br J Cancer (2008) 1.84
Meta-analysis of neoadjuvant treatment modalities and definitive non-surgical therapy for oesophageal squamous cell cancer. Br J Surg (2011) 1.82
Detection and localization of Mip-3alpha/LARC/Exodus, a macrophage proinflammatory chemokine, and its CCR6 receptor in human pancreatic cancer. Int J Cancer (1999) 1.81
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). Ann Oncol (2000) 1.79
ESPEN guidelines on nutrition in acute pancreatitis. European Society of Parenteral and Enteral Nutrition. Clin Nutr (2002) 1.75
Robot-assisted versus conventional laparoscopic fundoplication: short-term outcome of a pilot randomized controlled trial. Surg Endosc (2007) 1.75
Enhanced expression of vascular endothelial growth factor in human pancreatic cancer correlates with local disease progression. Clin Cancer Res (1997) 1.74
Role of serum carbohydrate antigen 19-9 and carcinoembryonic antigen in distinguishing between benign and invasive intraductal papillary mucinous neoplasm of the pancreas. Br J Surg (2010) 1.73
Adjuvant 5-fluorouracil and folinic acid vs observation for pancreatic cancer: composite data from the ESPAC-1 and -3(v1) trials. Br J Cancer (2009) 1.69
Heparanase expression in primary and metastatic pancreatic cancer. Cancer Res (2001) 1.67
Expression and in-situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer (1995) 1.67
The role of infection in acute pancreatitis. Gut (1999) 1.66
Imprinting of IGF2 P0 transcript and novel alternatively spliced INS-IGF2 isoforms show differences between mouse and human. Hum Mol Genet (2006) 1.63
The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene (1999) 1.63
Laparoscopic restorative proctocolectomy. Br J Surg (2005) 1.60
Microarray-based identification of differentially expressed growth- and metastasis-associated genes in pancreatic cancer. Cell Mol Life Sci (2003) 1.60
KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res (1996) 1.59
Clinical significance of liver ischaemia after pancreatic resection. Br J Surg (2011) 1.59
Loss of DNA mismatch repair: effects on the rate of mutation to drug resistance. J Natl Cancer Inst (1997) 1.58
The suprapubic approach for laparoscopic appendectomy. Surg Endosc (2001) 1.56
Risk factors for myocardial infarction in young women. Am J Epidemiol (1987) 1.55
The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer (2005) 1.54
Overexpression and activation of the tyrosine kinase Src in human pancreatic carcinoma. Biochem Biophys Res Commun (1998) 1.52
Randomized trial of duodenum-preserving pancreatic head resection versus pylorus-preserving Whipple in chronic pancreatitis. Am J Surg (1995) 1.52
High prevalence of Mycobacterium avium subspecies paratuberculosis IS900 DNA in gut tissues from individuals with Crohn's disease. Gut (2005) 1.51
In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res (1997) 1.50
Endoscopic retroperitoneal neurectomy for chronic pain after groin surgery. Br J Surg (2009) 1.50
A pancreatic cancer-specific expression profile. Oncogene (1996) 1.50
Randomized clinical trial of stapler versus clamp-crushing transection in elective liver resection. Br J Surg (2014) 1.50
Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg (2008) 1.50
Immune cell infiltration and growth-associated protein 43 expression correlate with pain in chronic pancreatitis. Gastroenterology (1997) 1.49
Persistent tardive dyskinesia: demographic and pharmacological risk factors. Acta Psychiatr Scand (1993) 1.48
Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer (1997) 1.47